Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Selumetinib therapy in patients with metastatic uveal melanoma.
Metastatic|Uveal Melanoma
DRUG: 75mg selumetinib|DRUG: placebo|DRUG: Dacarbazine
Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival (PFS) Using BICR According to RECIST 1.1., Progression free survival (PFS) using blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1). Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions., From Randomization, then every 6 weeks up until progression or death (whichever is sooner) assessed up to 15th May 2015
Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine in Terms of Objective Response Rate (ORR) by BICR, ORR at Week 6 using BICR according to RECIST 1.1, From Randomization, then every 6 weeks up until progression or death (whichever is sooner) assessed up to 15th May 2015|Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine in Terms of Change in Tumour Size at Week 6 by BICR, Percent change in tumour size at Week 6 using BICR according to RECIST 1.1, From Randomization, then every 6 weeks up until progression or death (whichever is sooner) assessed up to 15th May 2015|Assessment of the Overall Survival (OS) in Patients Taking Selumetinib in Combination With Dacarbazine Compared With Those Taking Placebo in Combination With Dacarbazine, Overall Survival, From Randomization, up until death assessed up to 15th May 2015
A randomised double-blind study to assess the efficacy of selumetinib (AZD6244, Hyd-Sulfate) in combination with Dacarbazine compared with placebo in combination with Dacarbazine as first systemic therapy in patients with metastatic uveal melanoma (SUMIT)